Non-cytomembrane PD-L1: An atypical target for cancer

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Programmed death ligand 1 (PD-L1) typically functions as a type I transmembrane protein interacting with its receptor, programmed cell death 1 (PD-1), to inhibit T cell responses and promote immune evasion.
• While targeting the PD-1/PD-L1 pathway has shown promise in cancer treatment, clinical responses are limited to specific malignancies, suggesting alternative mechanisms of immune resistance.

Purpose of the Study:

• To review the emerging roles of non-canonical PD-L1 localizations beyond the cell membrane.
• To explore the novel functions of nuclear PD-L1 (nPD-L1), cytoplasmic PD-L1 (cPD-L1), soluble PD-L1 (sPD-L1), and extracellular vesicle PD-L1 (EV PD-L1).
• To highlight the potential of these atypical PD-L1 forms as diagnostic markers and therapeutic targets in cancer treatment.

Main Methods:

• Literature review of recent studies on non-canonical PD-L1 localizations.
• Analysis of the functional implications of nPD-L1, cPD-L1, sPD-L1, and EV PD-L1.
• Synthesis of information regarding their roles in gene regulation, therapy prediction, and treatment resistance.

Main Results:

• Four atypical localizations of PD-L1 (nuclear, cytoplasmic, soluble, extracellular vesicle) have been identified.
• These non-canonical PD-L1 forms exhibit novel functions, including regulation of gene transcription.
• Non-cytomembrane PD-L1s are implicated in predicting therapeutic efficacy and understanding resistance to anti-PD-1/PD-L1 therapies.

Conclusions:

• Non-cytomembrane PD-L1 variants represent significant diagnostic biomarkers for cancer.
• These atypical PD-L1 forms are promising novel therapeutic targets for overcoming cancer treatment resistance.
• Understanding these diverse PD-L1 localizations is crucial for advancing cancer immunotherapy.